Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
CH2M was a premier global engineering, procurement, and construction management (EPCM) firm that served the life sciences, electronics, and infrastructure sectors. The company specialized in the design and delivery of complex pharmaceutical and biotechnology manufacturing facilities, including high-containment laboratories and sterile fill-finish suites. In December 2017, CH2M was acquired by Jacobs Engineering Group for approximately $3.3 billion, significantly expanding Jacobs' footprint in the global life sciences market. Today, the legacy CH2M expertise continues under the Jacobs brand, providing end-to-end solutions for major drug manufacturers worldwide. The company was particularly noted for its expertise in environmental health, water treatment, and sustainable infrastructure for large-scale industrial sites.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on CH2M.